Hypofractionation and Stereotactic Body Radiation Therapy in Inoperable Locally Advanced Non-small Cell Lung Cancer.
hypofractionation
non-small-cell lung cancer
radiotherapy
stereotactic body radiation therapy
Journal
Journal of clinical and translational research
ISSN: 2424-810X
Titre abrégé: J Clin Transl Res
Pays: Singapore
ID NLM: 101667205
Informations de publication
Date de publication:
22 Apr 2021
22 Apr 2021
Historique:
received:
20
10
2020
revised:
24
01
2021
accepted:
29
03
2021
entrez:
9
6
2021
pubmed:
10
6
2021
medline:
10
6
2021
Statut:
epublish
Résumé
Radiotherapy (RT) plays a key role in the control of locally advanced non-small cell lung cancer (LA-NSCLC). Throughout the years, different doses and fractionations of RT have been used in an attempt to optimize the results. Recently, special interest has been given to hypofractionation (hypoRT) and stereotactic body radiation therapy (SBRT). HypoRT is a relatively widespread treatment, although the accompanying level of evidence is limited. For its part, SBRT has been used specially to overdose specific areas of the disease as a boost after radiochemotherapy. In both cases, the study of how to integrate these RT tools with chemotherapy and immunotherapy is fundamental. In addition, the 2020 COVID-19 pandemic situation has sparked increased interest in hypofractionated treatments. In this review, we analyze the role of SBRT and hypoRT in the management of LA-NSCLC in accordance with current scientific evidence. The objective of this article is to introduce professionals to the role that hypoRT and SBRT can play in the treatment of LA-NSCLC to offer the best treatment to their patients.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Radiotherapy (RT) plays a key role in the control of locally advanced non-small cell lung cancer (LA-NSCLC). Throughout the years, different doses and fractionations of RT have been used in an attempt to optimize the results. Recently, special interest has been given to hypofractionation (hypoRT) and stereotactic body radiation therapy (SBRT). HypoRT is a relatively widespread treatment, although the accompanying level of evidence is limited. For its part, SBRT has been used specially to overdose specific areas of the disease as a boost after radiochemotherapy. In both cases, the study of how to integrate these RT tools with chemotherapy and immunotherapy is fundamental. In addition, the 2020 COVID-19 pandemic situation has sparked increased interest in hypofractionated treatments. In this review, we analyze the role of SBRT and hypoRT in the management of LA-NSCLC in accordance with current scientific evidence.
RELEVANCE FOR PATIENTS
UNASSIGNED
The objective of this article is to introduce professionals to the role that hypoRT and SBRT can play in the treatment of LA-NSCLC to offer the best treatment to their patients.
Identifiants
pubmed: 34104822
pii: jctres.07.202102.017
pmc: PMC8177839
Types de publication
Journal Article
Review
Langues
eng
Pagination
199-208Informations de copyright
Copyright: © Whioce Publishing Pte. Ltd.
Déclaration de conflit d'intérêts
The authors indicate no potential conflicts of interest.
Références
Radiol Med. 2019 Dec;124(12):1324-1332
pubmed: 31317381
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Radiat Oncol. 2013 Jul 10;8:179
pubmed: 23842112
Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1325-31
pubmed: 23265574
J Thorac Oncol. 2017 Nov;12(11):1687-1695
pubmed: 28919394
J Natl Cancer Inst. 2007 Mar 21;99(6):442-50
pubmed: 17374834
BMJ Open. 2019 Jan 29;9(1):e019903
pubmed: 30700475
Radiother Oncol. 2011 Jul;100(1):76-85
pubmed: 21757247
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):324-33
pubmed: 16168827
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e269-74
pubmed: 21477940
J Clin Oncol. 2012 Jan 10;30(2):172-8
pubmed: 22124104
Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):736-747
pubmed: 27639294
Clin Transl Oncol. 2017 Apr;19(4):440-447
pubmed: 27553602
Clin Lung Cancer. 2019 Jan;20(1):e1-e7
pubmed: 30268836
J Thorac Oncol. 2017 Feb;12(2):293-301
pubmed: 27743888
Clin Lung Cancer. 2017 Jul;18(4):436-440.e1
pubmed: 28215851
Radiother Oncol. 2016 Mar;118(3):447-52
pubmed: 26900092
Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1367-1377
pubmed: 27296040
Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):23-33
pubmed: 11163494
J Clin Oncol. 2010 Mar 10;28(8):1380-6
pubmed: 20142596
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):425-34
pubmed: 20980108
Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):667-71
pubmed: 15927409
Radiother Oncol. 2020 May;146:223-229
pubmed: 32342863
Radiat Oncol. 2013 Aug 17;8(1):201
pubmed: 23957889
Clin Oncol (R Coll Radiol). 2012 Aug;24(6):402-9
pubmed: 22516859
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21
pubmed: 28881918
Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):710-719
pubmed: 32275994
Clin Transl Oncol. 2019 Aug;21(8):992-1004
pubmed: 30644044
BMC Cancer. 2018 Nov 29;18(1):1183
pubmed: 30497431
Radiol Med. 2019 Feb;124(2):136-144
pubmed: 30368721
Front Oncol. 2012 Sep 26;2:124
pubmed: 23057009
Radiat Oncol. 2012 Mar 15;7:33
pubmed: 22420631
Radiother Oncol. 2017 Oct;125(1):62-65
pubmed: 28939179
Br J Radiol. 2016 Oct;89(1066):20160472
pubmed: 27556933
Radiother Oncol. 1999 Aug;52(2):129-36
pubmed: 10577698
Lancet. 2009 Aug 1;374(9687):379-86
pubmed: 19632716
Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):177-185
pubmed: 29487024
Radiother Oncol. 2020 Jan;142:224-229
pubmed: 31431387
Radiother Oncol. 2013 Oct;109(1):8-12
pubmed: 24094626
Radiother Oncol. 1999 Aug;52(2):137-48
pubmed: 10577699
Clin Oncol (R Coll Radiol). 2019 Feb;31(2):e1-e10
pubmed: 30415784
J Natl Cancer Inst. 2011 Oct 5;103(19):1452-60
pubmed: 21903745
Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):516-7
pubmed: 10661362
Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):652-659
pubmed: 29280459
Clin Lung Cancer. 2014 Jul;15(4):274-80
pubmed: 24685356
Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):741-7
pubmed: 15465190
Clin Lung Cancer. 2015 Mar;16(2):71-9
pubmed: 25450876
Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):348-56
pubmed: 12243807
Acta Oncol. 2020 Feb;59(2):164-170
pubmed: 31608751
Radiat Oncol. 2020 Feb 18;15(1):43
pubmed: 32070383
Thorac Cancer. 2020 Jun;11(6):1375-1385
pubmed: 32323484
Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1021-1027
pubmed: 27745983
J Thorac Oncol. 2021 Mar;16(3):428-438
pubmed: 33301984
J Thorac Dis. 2018 Aug;10(Suppl 21):S2465-S2473
pubmed: 30206492
Lancet Oncol. 2019 Apr;20(4):494-503
pubmed: 30770291
Int J Radiat Oncol Biol Phys. 2015 Sep 1;93(1):72-81
pubmed: 26279026
Radiother Oncol. 2017 Jul;124(1):11-17
pubmed: 28687397
Ann Oncol. 2009 Jan;20(1):98-102
pubmed: 18718891
Radiother Oncol. 2013 Oct;109(1):1-7
pubmed: 24128806
Eur J Cancer. 2007 Jan;43(1):114-21
pubmed: 17084621
Clin Oncol (R Coll Radiol). 2020 Aug;32(8):481-489
pubmed: 32405158
J Natl Cancer Inst. 2016 May 19;108(9):
pubmed: 27206636
J Clin Oncol. 2010 May 10;28(14):2475-80
pubmed: 20368547
Radiat Oncol. 2007 Jul 23;2:27
pubmed: 17659094
J Clin Oncol. 2013 Dec 1;31(34):4343-8
pubmed: 24145340
J Clin Oncol. 2017 May 1;35(13):1387-1394
pubmed: 28113017
Acta Oncol. 1988;27(2):131-46
pubmed: 3390344
Int J Radiat Oncol Biol Phys. 2020 Mar 15;106(4):733-742
pubmed: 31809876
Pract Radiat Oncol. 2015 May-Jun;5(3):149-155
pubmed: 25957185
BMC Cancer. 2020 Aug 26;20(1):806
pubmed: 32842974
JAMA Oncol. 2017 Oct 1;3(10):1358-1365
pubmed: 28570742
J Clin Oncol. 2012 Aug 1;30(22):2788-97
pubmed: 22753901
Lancet Oncol. 2015 Feb;16(2):187-99
pubmed: 25601342
Radiother Oncol. 2016 Mar;118(3):442-6
pubmed: 26900091
J Thorac Oncol. 2020 Jul;15(7):1137-1146
pubmed: 32360578
J Clin Oncol. 2017 Jan;35(1):56-62
pubmed: 28034064
Clin Lung Cancer. 2015 Nov;16(6):e203-12
pubmed: 25997733